Connect your AI

Capricor Therapeutics CAPR Price / book

Price / book at other companies

PfizerPFE

1.8×+0.2×

Sarepta Therapeutics, Inc.SRPT

1.5×-3.9×

Celldex TherapeuticsCLDX

4.6×+2.9×

VericelVCEL

4.6×-3.0×

Dyne Therapeutics, Inc.DYN

3.5×+1.7×

Viridian Therapeutics, Inc.VRDN

3.1×+1.3×

Other financials

Income statement

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

Market cap$1.71B+303%

Enterprise value$1.62B+308%

Profitability

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Calculated from Capricor Therapeutics’s reported figures.

market cap/total stockholders equity=6.3×

Based on the most recent quarter.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Capricor Therapeutics's price / book?: Capricor Therapeutics (CAPR) reported price / book of 6.3× in Q1 2026.
How has Capricor Therapeutics's price / book changed year-over-year?: Capricor Therapeutics's price / book increased by 84.7% year-over-year, from 3.4× to 6.3×.
What is the long-term trend for Capricor Therapeutics's price / book?: Over 5 years (2020 to 2025), Capricor Therapeutics's price / book has grown at a 11.8% compound annual growth rate (CAGR), from 2.9× to 5.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.